ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ENZY Enzymotec Ltd. - Ordinary Shares (delisted)

11.85
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Enzymotec Ltd. - Ordinary Shares (delisted) NASDAQ:ENZY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.85 0.05 199,999.95 0 01:00:00

Report of Foreign Issuer (6-k)

28/07/2017 1:51pm

Edgar (US Regulatory)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
 
For the month of July 2017
 
Commission File Number: 001-36073
 
                   ENZYMOTEC LTD.                     
(Translation of registrant’s name into English)
 
Sagi 2000 Industrial Area
P.O. Box 6
 Migdal Ha’Emeq 2310001, Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F  ☒          Form 40-F  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __

 


CONTENTS

Appointment of New Chief Financial Officer

On July 28, 2017, Enzymotec Ltd. (NASDAQ: ENZY) (the “ Company ”) announced the appointment of Dror Israel as its new Vice President and Chief Financial Officer in replacement of Oren Bryan, who is resigning from his position as Vice President and Chief Financial Officer of the Company, as previously reported by the Company on June 28, 2017. Mr. Israel will begin his employment at the Company on August 7, 2017, and will assume responsibilities following a transition period.
  
A copy of the press release making the foregoing announcement is appended to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  EYZMOTEC LTD.  
       
Dated: July 28, 2017
By:
/s/ Oren Bryan  
    Name: Oren Bryan  
    Title: Vice President and Chief Financial Officer  
       


EXHIBIT INDEX
 
The following exhibit is furnished as part of this Form 6-K:
 
Exhibit
 
Description
 99.1
 
Press release, dated July 28, 2017, announcing the appointment of Dror Israel as Vice President and Chief Financial Officer



1 Year ENZYMOTEC LTD. Chart

1 Year ENZYMOTEC LTD. Chart

1 Month ENZYMOTEC LTD. Chart

1 Month ENZYMOTEC LTD. Chart

Your Recent History

Delayed Upgrade Clock